Akero - AKRO Total Company Value-to-Revenue Ratio

Public company logo of Akero (AKRO)

Akero Therapeutics (AKRO) profitability is based on the commercialization of the EFX drug against NASH fibrosis. The price-to-sales ratio illustrates the business valuation dynamics, where 0.00 serves as the current parameter value. Progress in treating metabolic disorders is achieved through partnerships with clinics, while development flexibility is ensured by outsourcing tests to external laboratories.

AKRO Akero Therapeutics: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 12/20/2025

AKRO (Akero Therapeutics, Inc.): analytical breakdowns and indicator data

- money and cash flow information:
Fundamental company valuation:AKRO, akerotx.com
Mass-produced product of Akero

The prospects for Akero Therapeutics (AKRO) depend on the outcome of efruxifermin clinical trials and a potential acquisition by a pharma behemoth in the MASH therapy segment. The firm's valuation via the EV/Sales multiple relates the total enterprise value to revenue regardless of debt load, allowing investors to determine the premium paid for future growth rates or identify an undervalued asset by analyzing the price action on this chart.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Metsera Therapeutics (MTSR) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio moonlaketx.com (MLTX)|Company Value to Revenue Crinetics Pharmaceuticals CRNX|Enterprise Value-to-Revenue Ratio NewAmsterdam Pharma N.V. NAMS|Total Company Value-to-Revenue Ratio Soleno Therapeutics Inc (SLNO)|FOLD - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)